TOP study prospectively shows TP53-mutant EGFR lung cancer gains from first-line combination therapy, reshaping choices amid FLAURA2 and MARIPOSA.

Experts unpack TOP trial data on TP53 co-mutations, guiding first-line EGFR lung cancer choices between osimertinib alone or with chemo.

Both panelists acknowledge that most academic centers now adopt combination regimens as standard practice, with the TOP study providing additional supportive evidence rather than fundamentally changing treatment approaches. However, the data proves particularly valuable for clinicians who must prioritize resources or convince patients about combination therapy benefits.

Beyond TP53 mutations, several molecular and clinical characteristics influence treatment intensification decisions. Dr. Rodriguez emphasizes that patient factors including age, comorbidities, and chemotherapy tolerance capacity must be considered alongside molecular features.

A 50-year-old never-smoker presents with stage IV disease involving bone and contralateral lung metastases, excellent performance status, and molecular testing revealing EGFR exon 19 deletion with concurrent TP53 R175H mutation.

A 72-year-old patient presents with multiple baseline challenges: mild hypertension, stage 2 chronic kidney disease, hearing loss, and 3 small brain metastases planned for stereotactic radiosurgery.

The discussion addresses whether preserving sequencing flexibility should influence first-line treatment selection for patients with borderline fitness and small asymptomatic brain metastases.

Following first-line combination therapy, sequencing becomes more complex as chemotherapy exposure limits subsequent options.

Both panelists express enthusiasm about multiple emerging developments in EGFR-mutant NSCLC management.